The quality and consistency of plasmid DNA are foundational to the success of next-generation therapeutics, directly influencing vector efficacy, safety profiles, and regulatory acceptance. Sub-optimal plasmid manufacturing introduces significant variability, complicating the interpretation of preclinical data and jeopardizing IND timelines. A phase-appropriate approach to plasmid DNA production is designed to de-risk vector manufacturing and support accelerated 18-24 month IND submissions for AAV, lentiviral, and RNA programs under harmonized international guidelines.

Frequently Asked Questions

Plasmid DNA Manufacturing for Accelerated IND Timelines

Proven Intelligence in Vector Starting Materials.

The characterization of plasmid DNA is a primary control point in the manufacturing of viral vectors and RNA therapeutics. The integrity of this starting material dictates the quality of the final product, influencing everything from capsid packaging efficiency in AAV production to the translational fidelity of an mRNA payload. A failure to establish a robust and reproducible plasmid manufacturing process introduces a significant variable that can obscure the interpretation of preclinical data.

A well-defined vector prime is necessary to produce a predictable biological effect. The translational impact of this principle was observed in a preclinical nonhuman primate model evaluating an adenovirus-vectored vaccine strategy (PMID: 33658998). The study demonstrated that a consistent vector prime resulted in a more controlled downstream biological outcome. This reinforces the requirement for impeccably characterized starting materials, beginning with plasmid DNA, to generate the reproducible data required for IND-enabling toxicology studies.

A Phase-Appropriate and Forward-Looking Strategy

A manufacturing strategy that anticipates future regulatory requirements is fundamental to achieving an 18-24 month IND timeline. The process begins with producing high-quality, research-grade plasmids that are well-characterized, ensuring that early in vivo proof-of-concept studies are based on reliable material. This approach minimizes the risk of unexpected results when transitioning to a GxP-compliant manufacturing environment.

This continuity is a core part of our operational model. As one biotech partner noted:

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is the manufacturing partner for our AAV-vector based gene therapy candidate development.”

Our scientific team’s track record, which includes a 100% successful IND rate since 2019, was established prior to the formal launch of Franklin Biolabs in 2024. This deep experience informs our process optimization, which is designed to reduce timelines and costs without compromising quality.

Global Coordination for Next-Generation Therapeutics

For sponsors targeting international clinical trials, plasmid manufacturing must align with global regulatory standards from the outset. We develop manufacturing and analytical documentation in accordance with ICH guidelines, creating a unified CMC data package. This harmonized approach supports efficient preparation of regulatory filings for multiple agencies, including the FDA, EMA, and MHRA.

This integrated strategy is executed within our >100,000 sq ft of manufacturing and analytics facilities, providing a centralized path from plasmid production to vector manufacturing and preclinical testing. For more information on our comprehensive capabilities, please see our core Vector | CMC | Analytics Services page.